Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel P Murray

Showing results (41-50 of 78) with videos related to

Pageof 8
Sort By:
Journal of Oncology|September 12, 2014
Primary circulating prostate cells are not detected in men with low grade small volume prostate cancerNigel P Murray, Eduardo Reyes, Cynthia Fuentealba, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|October 31, 2015
Comparison of the Walz Nomogram and Presence of Secondary Circulating Prostate Cells for Predicting Early Biochemical Failure after Radical Prostatectomy for Prostate Cancer in Chilean MenNigel P Murray, Eduardo Reyes, Nelson Orellana, et al.
Archivos Espanoles De Urologia|October 14, 2014
Elimination of primary circulating prostate cells after radical prostatectomy for prostate cancer decreases the risk of future biochemical failureNigel P Murray, Eduardo Reyes, Nelson Orellana, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|November 26, 2014
Extended use of P504S positive primary circulating prostate cell detection to determine the need for initial prostate biopsy in a prostate cancer screening program in ChileNigel P Murray, Eduardo Reyes, Cynthia Fuentealba, et al.
Archivos Espanoles De Urologia|February 12, 2019
[Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy.]Nigel P Murray, Sócrates Aedo, Eduardo Reyes, et al.
Archivos Espanoles De Urologia|September 22, 2022
The CAPRA-S Score and Immune Dysfunction as a Guide to Outcome in Men Treated with Prostatectomy Radical as Mono-Therapy for Prostate CancerNigel P Murray, Socrates Aedo, Cynthia Fuentealba, et al.
Case Reports in Hematology|September 26, 2025
Intravascular Lymphoma Presenting as Multiple Endocrine Failure, Transforming Into the Hemophagocytic Variant, and Relapsing as a Thrombotic MicroangiopathyNigel P Murray, Cinthia Escobar, Enrique Ramos, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|October 29, 2023
The Possible Role of Matrix Metalloprotienase-2 in the Relapse in Patients with Stage II Colon Cancer Treated by Curative SurgeryNigel P Murray, Ricardo Villalon, Socrates Aedo, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|September 2, 2021
Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcomeNigel P Murray, Ricardo Villalon, Dan Hartmann, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|February 28, 2022
Improvement in the Neutrophil-Lymphocyte Ratio after Combined Fluorouracil, Leucovorina and Oxaliplatino based (FOLFOX) Chemotherapy for Stage III Colon Cancer is Associated with Improved Minimal Residual Disease and OutcomeNigel P Murray, Ricardo Villalon, Dan Hartmann, et al.
Pageof 8

Showing results (41-50 of 78) with videos related to

Sort By:
Pageof 8
Journal of Oncology|September 12, 2014
Primary circulating prostate cells are not detected in men with low grade small volume prostate cancerNigel P Murray, Eduardo Reyes, Cynthia Fuentealba, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|October 31, 2015
Comparison of the Walz Nomogram and Presence of Secondary Circulating Prostate Cells for Predicting Early Biochemical Failure after Radical Prostatectomy for Prostate Cancer in Chilean MenNigel P Murray, Eduardo Reyes, Nelson Orellana, et al.
Archivos Espanoles De Urologia|October 14, 2014
Elimination of primary circulating prostate cells after radical prostatectomy for prostate cancer decreases the risk of future biochemical failureNigel P Murray, Eduardo Reyes, Nelson Orellana, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|November 26, 2014
Extended use of P504S positive primary circulating prostate cell detection to determine the need for initial prostate biopsy in a prostate cancer screening program in ChileNigel P Murray, Eduardo Reyes, Cynthia Fuentealba, et al.
Archivos Espanoles De Urologia|February 12, 2019
[Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy.]Nigel P Murray, Sócrates Aedo, Eduardo Reyes, et al.
Archivos Espanoles De Urologia|September 22, 2022
The CAPRA-S Score and Immune Dysfunction as a Guide to Outcome in Men Treated with Prostatectomy Radical as Mono-Therapy for Prostate CancerNigel P Murray, Socrates Aedo, Cynthia Fuentealba, et al.
Case Reports in Hematology|September 26, 2025
Intravascular Lymphoma Presenting as Multiple Endocrine Failure, Transforming Into the Hemophagocytic Variant, and Relapsing as a Thrombotic MicroangiopathyNigel P Murray, Cinthia Escobar, Enrique Ramos, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|October 29, 2023
The Possible Role of Matrix Metalloprotienase-2 in the Relapse in Patients with Stage II Colon Cancer Treated by Curative SurgeryNigel P Murray, Ricardo Villalon, Socrates Aedo, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|September 2, 2021
Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcomeNigel P Murray, Ricardo Villalon, Dan Hartmann, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|February 28, 2022
Improvement in the Neutrophil-Lymphocyte Ratio after Combined Fluorouracil, Leucovorina and Oxaliplatino based (FOLFOX) Chemotherapy for Stage III Colon Cancer is Associated with Improved Minimal Residual Disease and OutcomeNigel P Murray, Ricardo Villalon, Dan Hartmann, et al.
Pageof 8